Skip to main content
LABT
NASDAQ Life Sciences

Lakewood-Amedex Registers 4.5M Additional Shares for Series C Holder Resale

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.94
Mkt Cap
$4.716M
52W Low
$1.66
52W High
$98.2
52W Position info
17% above low
Off High info
98% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

LABT sits 17% above its 52-week low of $1.66 on light trading volume (0.2× avg).

Summary

Lakewood-Amedex filed an S-1 to register 4,512,400 additional shares for resale by its Series C Preferred holder, Shakawe Capital LLC, after the reverse split increased the maximum conversion amount at the $1.00 floor price.


Key Events · Financing and Capital Events · LABT

  • 4.5M Additional Shares Registered for Resale

    The S-1 registers 4,512,400 shares of common stock for resale by Shakawe Capital LLC, the holder of the remaining 451,240 Series C Preferred shares.

  • Reverse Split Inflated Conversion Overhang

    The 1:10 reverse split did not adjust the $1.00 conversion floor, increasing the maximum common shares issuable from 937,500 to 4,512,400 for the remaining preferred stock.

  • No Proceeds to Company

    Lakewood-Amedex will receive no proceeds from any sales by the selling stockholder; all proceeds go to Shakawe Capital LLC.

  • Prior Conversions Exhausted First Registration

    486,260 Series C shares have already converted into 937,500 common shares, fully using the prior S-1 registration, leaving this new filing as the only path for the remaining overhang.


Analysis · LABT · Life Sciences

The 1:10 reverse split in June 2026 did not adjust the $1.00 conversion floor on the Series C Preferred Stock, which mechanically increased the maximum number of common shares issuable upon conversion. This S-1 registers an additional 4,512,400 shares for resale by Shakawe Capital LLC — nearly double the 2,369,688 shares currently outstanding. The company receives no proceeds from these sales, and the holder can sell at market prices from time to time, creating a significant overhang on the stock. Combined with the company's going-concern warning and the pending shareholder vote on an 8x authorized share increase, this filing quantifies a dilution path that existing holders must absorb.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LABT was trading at $1.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $1.66 to $98.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LABT - Latest Insights

LABT
Nov 16, 2026, 5:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.245
Real-time Price: $0.2275 info
Change: -$0.0175 (-7%) info
Market Cap: $2.083M info
LABT
Nov 16, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.230
Real-time Price: $0.2275 info
Change: -$0.0025 (-1%) info
Market Cap: $2.083M info
LABT
Nov 10, 2026, 5:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.402
Real-time Price: $0.2275 info
Change: -$0.1745 (-43%) info
Market Cap: $2.083M info
LABT
Sep 28, 2026, 5:49 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.2275 info
Change: -$0.8425 (-79%) info
Market Cap: $2.083M info
LABT
Sep 24, 2026, 8:02 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.80
Real-time Price: $0.2275 info
Change: -$1.57 (-87%) info
Market Cap: $2.083M info